The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management
Purpose: Lymphoma, the most predominant neoplastic disorder, is divided into Hodgkin and Non-Hodgkin Lymphoma classifications. Immunotherapeutic modalities have emerged as essential methodologies in combating lymphoid malignancies. Chimeric Antigen Receptor (CAR) T cells exhibit promising responses...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tabriz University of Medical Sciences
2024-07-01
|
| Series: | Advanced Pharmaceutical Bulletin |
| Subjects: | |
| Online Access: | https://apb.tbzmed.ac.ir/PDF/apb-14-314.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849722144716488704 |
|---|---|
| author | Dito Anurogo Dewi Luthfiana Nuralfin Anripa Apriliani Ismi Fauziah Maratu Soleha Laila Rahmah Hana Ratnawati Teresa Liliana Wargasetia Sari Eka Pratiwi Riswal Nafi Siregar Ratis Nour Sholichah Muhammad Sobri Maulana Taruna Ikrar Yu Hsiang Chang Jiantai Timothy Qiu |
| author_facet | Dito Anurogo Dewi Luthfiana Nuralfin Anripa Apriliani Ismi Fauziah Maratu Soleha Laila Rahmah Hana Ratnawati Teresa Liliana Wargasetia Sari Eka Pratiwi Riswal Nafi Siregar Ratis Nour Sholichah Muhammad Sobri Maulana Taruna Ikrar Yu Hsiang Chang Jiantai Timothy Qiu |
| author_sort | Dito Anurogo |
| collection | DOAJ |
| description | Purpose: Lymphoma, the most predominant neoplastic disorder, is divided into Hodgkin and Non-Hodgkin Lymphoma classifications. Immunotherapeutic modalities have emerged as essential methodologies in combating lymphoid malignancies. Chimeric Antigen Receptor (CAR) T cells exhibit promising responses in chemotherapy-resistant B-cell non-Hodgkin lymphoma cases. Methods: This comprehensive review delineates the advancement of CAR-T cell therapy as an immunotherapeutic instrument, the selection of lymphoma antigens for CAR-T cell targeting, and the conceptualization, synthesis, and deployment of CAR-T cells. Furthermore, it encompasses the advantages and disadvantages of CAR-T cell therapy and the prospective horizons of CAR-T cells from a computational research perspective. In order to improve the design and functionality of artificial CARs, there is a need for TCR recognition investigation, followed by the implementation of a quality surveillance methodology. Results: Various lymphoma antigens are amenable to CAR-T cell targeting, such as CD19, CD20, CD22, CD30, the kappa light chain, and ROR1. A notable merit of CAR-T cell therapy is the augmentation of the immune system’s capacity to generate tumoricidal activity in patients exhibiting chemotherapy-resistant lymphoma. Nevertheless, it also introduces manufacturing impediments that are laborious, technologically demanding, and financially burdensome. Physical, physicochemical, and physiological limitations further exacerbate the challenge of treating solid neoplasms with CAR-T cells. Conclusion: While the efficacy and safety of CAR-T cell immunotherapy remain subjects of fervent investigation, the promise of this cutting-edge technology offers valuable insights for the future evolution of lymphoma treatment management approaches. Moreover, CAR-T cell therapies potentially benefit patients, motivating regulatory bodies to foster international collaboration. |
| format | Article |
| id | doaj-art-a00e60cb4cde43b5b7fb2e41b49eec89 |
| institution | DOAJ |
| issn | 2228-5881 2251-7308 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Tabriz University of Medical Sciences |
| record_format | Article |
| series | Advanced Pharmaceutical Bulletin |
| spelling | doaj-art-a00e60cb4cde43b5b7fb2e41b49eec892025-08-20T03:11:26ZengTabriz University of Medical SciencesAdvanced Pharmaceutical Bulletin2228-58812251-73082024-07-0114231433010.34172/apb.2024.034apb-40755The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma ManagementDito Anurogo0Dewi Luthfiana1Nuralfin Anripa2Apriliani Ismi Fauziah3Maratu Soleha4Laila Rahmah5Hana Ratnawati6Teresa Liliana Wargasetia7Sari Eka Pratiwi8Riswal Nafi Siregar9Ratis Nour Sholichah10Muhammad Sobri Maulana11Taruna Ikrar12Yu Hsiang Chang13Jiantai Timothy Qiu14International Ph.D. Program in Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei, 110301, Taiwan.Bioinformatics Research Center, Indonesian Institute of Bioinformatics (INBIO), Malang, East Java , 65162, Indonesia.Department of Environmental Science, Dumoga University, Kotamobagu, South Sulawesi, 95711, Indonesia.MSc Program in Tropical Medicine, Kaohsiung Medical University, Kaohsiung City, 807378, Taiwan.National Research and Innovation Agency (BRIN), Central Jakarta, 10340, Indonesia.Department of Digital Health, School of Medicine, Tehran University of Medical Sciences, Tehran, 1416634793, Iran.Faculty of Medicine, Maranatha Christian University, Bandung, West Java, 40164, Indonesia.Faculty of Medicine, Maranatha Christian University, Bandung, West Java, 40164, Indonesia.Department of Biology and Pathobiology, Faculty of Medicine, Tanjungpura University, Pontianak, West Kalimantan, 78115, Indonesia.National Research and Innovation Agency (BRIN), Central Jakarta, 10340, Indonesia.Department of Biotechnology, Postgraduate School of Gadjah Mada University, Yogyakarta, 55284, Indonesia.Community Health Center (Puskesmas) Temon 1, Kulon Progo, Special Region of Yogyakarta, 55654, Indonesia.Director of Members-at-Large, International Association of Medical Regulatory Authorities (IAMRA), Texas, 76039, USA.International Ph.D. Program in Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei, 110301, Taiwan.International Ph.D. Program in Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei, 110301, Taiwan.Purpose: Lymphoma, the most predominant neoplastic disorder, is divided into Hodgkin and Non-Hodgkin Lymphoma classifications. Immunotherapeutic modalities have emerged as essential methodologies in combating lymphoid malignancies. Chimeric Antigen Receptor (CAR) T cells exhibit promising responses in chemotherapy-resistant B-cell non-Hodgkin lymphoma cases. Methods: This comprehensive review delineates the advancement of CAR-T cell therapy as an immunotherapeutic instrument, the selection of lymphoma antigens for CAR-T cell targeting, and the conceptualization, synthesis, and deployment of CAR-T cells. Furthermore, it encompasses the advantages and disadvantages of CAR-T cell therapy and the prospective horizons of CAR-T cells from a computational research perspective. In order to improve the design and functionality of artificial CARs, there is a need for TCR recognition investigation, followed by the implementation of a quality surveillance methodology. Results: Various lymphoma antigens are amenable to CAR-T cell targeting, such as CD19, CD20, CD22, CD30, the kappa light chain, and ROR1. A notable merit of CAR-T cell therapy is the augmentation of the immune system’s capacity to generate tumoricidal activity in patients exhibiting chemotherapy-resistant lymphoma. Nevertheless, it also introduces manufacturing impediments that are laborious, technologically demanding, and financially burdensome. Physical, physicochemical, and physiological limitations further exacerbate the challenge of treating solid neoplasms with CAR-T cells. Conclusion: While the efficacy and safety of CAR-T cell immunotherapy remain subjects of fervent investigation, the promise of this cutting-edge technology offers valuable insights for the future evolution of lymphoma treatment management approaches. Moreover, CAR-T cell therapies potentially benefit patients, motivating regulatory bodies to foster international collaboration.https://apb.tbzmed.ac.ir/PDF/apb-14-314.pdfcar-t cellslymphomamanagement |
| spellingShingle | Dito Anurogo Dewi Luthfiana Nuralfin Anripa Apriliani Ismi Fauziah Maratu Soleha Laila Rahmah Hana Ratnawati Teresa Liliana Wargasetia Sari Eka Pratiwi Riswal Nafi Siregar Ratis Nour Sholichah Muhammad Sobri Maulana Taruna Ikrar Yu Hsiang Chang Jiantai Timothy Qiu The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management Advanced Pharmaceutical Bulletin car-t cells lymphoma management |
| title | The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management |
| title_full | The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management |
| title_fullStr | The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management |
| title_full_unstemmed | The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management |
| title_short | The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management |
| title_sort | art of bioimmunogenomics bigs 5 0 in car t cell therapy for lymphoma management |
| topic | car-t cells lymphoma management |
| url | https://apb.tbzmed.ac.ir/PDF/apb-14-314.pdf |
| work_keys_str_mv | AT ditoanurogo theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT dewiluthfiana theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT nuralfinanripa theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT aprilianiismifauziah theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT maratusoleha theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT lailarahmah theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT hanaratnawati theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT teresalilianawargasetia theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT sariekapratiwi theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT riswalnafisiregar theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT ratisnoursholichah theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT muhammadsobrimaulana theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT tarunaikrar theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT yuhsiangchang theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT jiantaitimothyqiu theartofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT ditoanurogo artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT dewiluthfiana artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT nuralfinanripa artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT aprilianiismifauziah artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT maratusoleha artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT lailarahmah artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT hanaratnawati artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT teresalilianawargasetia artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT sariekapratiwi artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT riswalnafisiregar artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT ratisnoursholichah artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT muhammadsobrimaulana artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT tarunaikrar artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT yuhsiangchang artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement AT jiantaitimothyqiu artofbioimmunogenomicsbigs50incartcelltherapyforlymphomamanagement |